August 2026 Monthly Update
The next monthly meeting of the Jersey Shore Prostate Cancer Support Group is on Thursday, August 20th at 7:00 pm in-person or online at the Monmouth County Library, 125 Symmes Drive, Manalapan, NJ.
The library requires that you register in advance for each session for both in-person and online meetings.
https://monmouthcountylib.libcal.com/event/17199501
******************************************************************************************************************************************************
The Prostate Cancer Foundation (PCF) has issued "Prostate Cancer Testing". This pamphlet discussed new types of tests to help guide prostate cancer diagnosis and treatment. (click on the link below)
https://www.pcf.org/wp-content/uploads/2026/07/Prostate-Cancer-Testing_printable.pdf
******************************************************************************************************************************************************
The 8th Annual New York City Prostate Cancer Summit is taking place on Sunday, September 20th, 2026, from 10:30 am-2:00 pm.
Prostate cancer experts from Weill Cornell Medicine, Columbia University Irving Medical Center, and Memorial Sloan Kettering Cancer Center are coming together for this annual program to share the latest prostate cancer updates with patients, families and caregivers.
Topics at this year’s event include: the role of exercise, immunotherapy and other up and coming areas of prostate cancer treatment, navigating education and support resources, and much more! The 2026 NYC Prostate Cancer Summit will feature multidisciplinary clinicians and team members from medical oncology, radiation oncology, urology, nutrition, and more. There will also be smaller group lunch discussions featuring a wide range of care team experts.
All those impacted by prostate cancer are welcome to attend.
The event is free, but RSVP is required. Save your spot today: www.prostatesummit.org
Sunday, September 20, 2026
10:30am-2:00pm (doors open 10:00 am)
New York Academy of Medicine
1216 Fifth Ave | New York, NY 10029
*************************************************************************************************************************************
The FDA has expanded its approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). This type of prostate cancer is also called androgen pathway modulation-naïve or sensitive.
For men with metastatic prostate cancer, this means access to a more targeted treatment path from the very start.
How Pluvicto Works
Pluvicto is an intravenous medicine that targets PSMA, a protein found on most prostate cancer cells. It travels through your blood and delivers radiation to cells with PSMA on their surface, killing them. While on Pluvicto, you will also take an androgen receptor pathway inhibitor (ARPI) medicine and androgen deprivation therapy (ADT).